131 completed, 64 recruiting, 42 unknown, 33 active not recruiting. 148 Phase 2, 76 Phase 1, 36 Not applicable, 20 Phase 3, 6 Early Phase 1.
Follow Hodgkin Lymphoma: new trials by email Literature Review of Hodgkin Lymphoma trials Research Report on Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma | Phase 1 | Not yet recruiting | The Methodist Hospital Research Institute | 21 | 2027-01-15 | 2026-07-27 |
| Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Fludarabine, Cyclophosphamide, CD70.CAR NK Cells - Large B-cell Lymphoma, Hodgkin Lymphoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 100 | 2026-12-28 | 2026-07-15 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity 68Ga-Galmydar, PET/MRI, 18F-FDG - Lymphoma Cancer, Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 36 | 2026-11-01 | 2026-09-24 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma Proton Therapy (Adaptive) - Pediatric Solid Tumors, Rhabdomyosarcoma | Not applicable | Recruiting | St. Jude Children's Research Hospital | 100 | 2026-08-20 | 2026-08-21 |
| Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL Nivolumab, Doxorubicin Hydrochloride, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 15 | 2026-08-19 | 2026-08-31 |
| CD45BE-HSPC + CART-45 Cells CART-45 cells, CD45BE-HSPC - B-Cell Non-Hodgkin Lymphoma (NHL), Richter's Transformation | Phase 1 | Recruiting | University of Pennsylvania | 42 | 2026-08-05 | 2026-08-10 |
| PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma 20 Gy Involved site radiotherapy, 30 Gy Involved site radiotherapy - Hodgkin Lymphoma | Phase 3 | Recruiting | Fondazione Italiana Linfomi - ETS | 518 | 2026-07-10 | 2026-08-27 |
| PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma PD-1+JAK1i, PD-1 - Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 112 | 2026-06-30 | 2026-06-11 |
| Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma High Intensity Interval Training (HIIT) - Hodgkin Lymphoma | Not applicable | Recruiting | St. Jude Children's Research Hospital | 20 | 2026-06-08 | 2026-06-10 |
| Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies Fludarabine, TGFBR2 KO CAR27/IL-15 NK cells, Cyclophosphamide - Lymphoid, Hodgkin Lymphoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 60 | 2026-05-28 | 2026-09-08 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| A Phase I Study of JLM019 Injection JLM019 Injection - Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma | Phase 1 | Recruiting | Jecho Biopharmaceuticals Co., Ltd. | 115 | 2026-01-13 | 2026-06-03 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Prognostic Model of Elderly Hodgkin Lymphoma in China Hodgkin Lymphoma | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 400 | 2025-12-09 | 2026-01-28 | |
| Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas C7R.CD30.CAR-EBVST cells - CD30-Positive Diffuse Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type | Phase 1 | Recruiting | Baylor College of Medicine | 90 | 2025-10-27 | 2026-10-02 |
| Mozobil for Autologous Hematopoietic Stem Cell Transplantation Plerixafor, Gcsf - Multiple Myeloma, Hodgkin Lymphoma | Phase 2 | Recruiting | Thomas Jefferson University | 100 | 2025-10-16 | 2025-11-28 |
Showing 20 of 317. Sign in to see all of them.
Hodgkin Disease (317) · Lymphoma, Non-Hodgkin (119) · Myelodysplastic Syndromes (56) · Leukemia, Myeloid, Acute (50) · Multiple Myeloma (49) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (46) · Lymphoma (44) · Leukemia, Lymphocytic, Chronic, B-Cell (39) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (36) · Myeloproliferative Disorders (25) · Leukemia (24) · Lymphoma, Large B-Cell, Diffuse (23) · Hematologic Neoplasms (19) · Lymphoma, Follicular (19) · Lymphoma, Mantle-Cell (18)
Hemic and Lymphatic Diseases (316) · Immune System Diseases (316) · Immunoproliferative Disorders (316) · Lymphatic Diseases (315) · Neoplasms by Histologic Type (315) · Lymphoproliferative Disorders (313) · Neoplasms (303) · Lymphoma (273) · Hematologic Diseases (101) · Pathological Conditions, Signs and Symptoms (85) · Pathologic Processes (79) · Disease Attributes (73) · Bone Marrow Diseases (68) · Leukemia, Lymphoid (66) · Leukemia (65)
Cyclophosphamide (42) · Brentuximab Vedotin (34) · Doxorubicin (30) · Dacarbazine (25) · Nivolumab (24) · Mycophenolic Acid (23) · Whole-Body Irradiation (23) · Vinblastine (22) · fludarabine (22) · fludarabine phosphate (19) · pembrolizumab (19) · Etoposide (16) · Bleomycin (14) · Granulocyte Colony-Stimulating Factor (13) · Filgrastim (12)
St. Jude Children's Research Hospital (16) · Memorial Sloan Kettering Cancer Center (11) · City of Hope Medical Center (10) · M.D. Anderson Cancer Center (10) · University of Cologne (9) · Fondazione Italiana Linfomi - ETS (7) · Baylor College of Medicine (6) · Masonic Cancer Center, University of Minnesota (5) · Mayo Clinic (5) · Merck Sharp & Dohme LLC (5) · National Cancer Institute (NCI) (5) · St. Petersburg State Pavlov Medical University (5) · Takeda (5) · Chinese PLA General Hospital (4) · The Lymphoma Academic Research Organisation (4)
United States (184) · Italy (30) · China (22) · France (18) · Germany (15) · United Kingdom (15) · Spain (13) · Australia (11) · Belgium (11) · Canada (10) · Russia (10) · Denmark (8) · Netherlands (8) · Brazil (7) · Czechia (7)
Alison Moskowitz, MD (4) · Andreas Engert, Prof. (4) · Peter Borchmann, Prof. (4) · Anas Younes, MD (3) · Ryotaro Nakamura, MD (3) · Alessandro M Gianni, MD (2) · Antonio Pinto, MD (2) · Arnon Nagler, MD (2) · Brandon Triplett, MD (2) · Graham Collins (2) · Hayder Saeed, MD (2)
PMID 40135712, PMID 30010775, PMID 31395089, PMID 39620432, PMID 41074963, PMID 12377653, PMID 15837968, PMID 17846017, PMID 18258763, PMID 21166786, PMID 21454450, PMID 21774708, PMID 21841163, PMID 22149921, PMID 22735430, PMID 23275102, PMID 23459515, PMID 24121121, PMID 24239220, PMID 24573552, PMID 24692582, PMID 25195991, PMID 25311218, PMID 25482239, PMID 25887777, PMID 25964643, PMID 26729448, PMID 27269947, PMID 27354476, PMID 27458003, PMID 27574190, PMID 27760761, PMID 28278727, PMID 28327905, PMID 28441111, PMID 28490569, PMID 29141948, PMID 29224502, PMID 29229594, PMID 29276022, PMID 29360414, PMID 29774169, PMID 29925499, PMID 30200906, PMID 30617130, PMID 30937889, PMID 30952672, PMID 31012356, PMID 31039052, PMID 31088808
P30CA033572 (5), 2017 (4), 2023 (4), 2014 (2), 2015 (2), 2018 (2), 2005 (1), 2009 (1), 2019 (1), 4UL1TR000427-10 (1), K07CA136966 (1), P01CA015396 (1), P01CA049605 (1), P01CA078902 (1), P30CA014089 (1)